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from urinary tract infection and preventing subsequent 
renal parenchymal defects is the prompt diagnosis and 
treatment of the infection. This is particularly important 
in infants and young children, in whom the diagnosis 
can easily be missed.
NICE has developed tools to help organisations 
implement the guidance (see www.nice.org.uk/page.
aspx?o=tools).
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Milk alkali syndrome is easily missed and 
should be considered in all patients who 
present with hypercalcaemia 
Milk alkali syndrome is the third commonest cause     
of hospital admissions for hypercalcaemia,   1 2 but the 
diagnosis is often missed.2-5 Misdiagnosis can lead to 
unnecessary and potentially invasive investigations and 
inappropriate treatment
case report
A 76 year old woman was referred to a gastroenter-
ology outpatient clinic with altered bowel habit. She 
had a six month history of alternating constipation and 
diarrhoea, and she admitted to polydipsia, polyuria, 
and nocturia. She had no nausea, vomiting, abdominal 
pain, or weight loss. Her regular prescriptions included 
salbutamol inhaler, a calcium channel blocker, and 
ibuprofen for chronic obstructive pulmonary disease, 
hypertension, and osteoarthritis. She had a history of 
dyspepsia caused by gastric erosions noted on gastro-
scopy. She denied taking vitamin supplements or other 
over the counter medications. 
Clinical examination was unremarkable, but routine 
investigations showed hypercalcaemia (table). She was 
admitted for immediate treatment with intravenous 
fluids and intravenous infusion of disodium pamidronate 
90 mg. On the second day after admission, her serum 
calcium concentration was normal. The results of 
additional investigations taken before disodium 
pamidronate was started became available later (table). 
There was no clinical evidence of acidosis, such as 
Kussmaul’s respiration, though we did not test her 
arterial pH. Results of chest radiography, abdominal 
computed tomography, bone scan, and mammography 
were all normal. Her serum calcium concentrations 
remained normal without further need for disodium 
pamidronate infusions or intravenous fluids.
After we had treated her hypercalcaemia, careful 
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Laboratory test results (serum concentrations unless 
stated otherwise) from patient with milk alkali syndrome
At presentation Result (normal range)
Calcium (mmol/l) 3.45 (2.25-2.7)
Phosphate (mmol/l) 1.36 (0.8-1.44)
Creatinine (mol/l) 124 (65-120)
Intact parathyroid hormone (ng/l ) 8 (5-60)
25 (OH)D3* (nmol/l ) 59 (10-50)
Urine calcium/creatinine ratio (mmol) 1.03 (0-0.7)
Free thyroxine (pmol/l) 18 (11-23)
Thyroid stimulating hormone (mU/l) 1.76 (0.3-4.7)
Random cortisol (nmol/l) 611
Angiotensin converting enzyme (U/l) 19 (8-52)
Day 2
Calcium (mmol/l) 2.55 (2.25-2.7)
Creatinine (mol/l) 111 (65-120)
Day 6
Calcium (mmol/l) 2.35 (2.25-2.7)
Creatinine (mol/l) 94
Three months after discharge from hospital
Calcium (mmol/l) 2.46 (2.25-2.7)
Creatinine (mol/l) 83 (65-120)
Intact parathyroid hormone (ng/l) 25 (5-60)
*25 hydroxycholecalciferol.
review of her drug history showed that for the previous 
two years she had been taking six to eight indigestion 
tablets daily (equal to 5.5 g calcium carbonate a day) to 
alleviate her dyspepsia. She denied any concomitant 
consumption of milk or milk products. The patient 
was advised to discontinue these tablets and the 
ibuprofen. Her dyspepsia did not recur, and she did 
not require further gastrointestinal investigations or 
the introduction of proton pump inhibitors. She was 
discharged with normal calcium concentrations (2.35 
mmol/l) six days after admission. Three months later, 
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during a scheduled follow-up, results of biochemistry 
tests remained normal (table).
discussion
Milk alkali syndrome is a hypercalcaemic disorder ini-
tially described in association with excessive consump-
tion of milk and sodium bicarbonate for the treatment of 
peptic ulcer disease (the Sippy diet).3 4 6 7 The syndrome 
became rare after the introduction of H2 blockers and 
proton pump inhibitors in clinical practice. Recent data, 
however, suggest a rising incidence of milk alkali syn-
drome as a cause of severe hypercalcaemia, probably 
as a result of increasing use of medications containing 
calcium carbonate (mainly dispensed over the counter) 
and other calcium rich products.1 3 4 Two series of 100 
and 125 patients have shown that milk alkali syndrome 
is the third most common cause of hospital admissions 
for hypercalcaemia.1 2 The diagnosis is based on a his-
tory of ingestion of calcium rich compounds, concord-
ant biochemical findings, and exclusion of other causes, 
the commonest being primary hyperparathyroidism 
(associated with an raised serum parathormone) and 
hypercalcaemia of malignancy (hence the screening 
tests for malignancy). Rarer causes of hypercalcaemia 
include thyrotoxicosis (excluded by normal serum thy-
roid stimulating hormone), Addison’s disease (excluded 
by a high normal serum cortisol concentration) and 
sarcoidosis (unlikely in view of the normal results for 
angiotensin converting enzyme).
Milk alkali syndrome should be considered in all 
patients who present with hypercalcaemia. Preparations 
that contain calcium carbonate are widely used for 
many medical conditions, including simple dyspepsia, 
renal failure (as phosphate binding agents), and 
prophylaxis or treatment of osteoporosis. The key 
element to the development of milk alkali syndrome is 
an increased calcium intake, which is also responsible 
for the development of metabolic alkalosis and renal 
failure. The presence of the two latter features defines 
the advanced form of milk alkali syndrome and 
progression to it depends on several factors, including 
individual differences in intestinal absorption of 
calcium, old age, decreased gastric pH, and pre-existing 
renal failure. The daily amount of ingested calcium 
plays an important role in the pathogenesis of milk 
alkali syndrome, with quantities ranging from 2-15 g 
calcium carbonate a day being implicated.3 6-9
Early diagnosis and treatment of hypercalcaemia 
is associated with a favourable outcome.3 7 8 Altered 
mental status caused by hypercalcaemia at the time 
of presentation may affect the accuracy of the history 
from the patient and pose an obstacle to timely 
diagnosis and management. A careful history of drug 
use should always be taken from patients who present 
with hypercalcaemia and corroborated by relatives, 
carers, or the patient’s primary care physician. The 
management of milk alkali syndrome is withdrawal of 
the offending medications and correction of volume 
depletion with or without calciuresis. Although 
bisphosphonates have been used, they should be 
avoided as the above measures are usually effective, 
increased bone resorption is not thought to play a 
important pathogenetic role, and hypocalcaemia can 
result from bisphosphonate use.5
Given that calcium carbonate has replaced milk 
products as the main source of calcium leading to the 
syndrome, we suggest that “calcium alkali syndrome” 
is a more appropriate name.
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The distance between yes and no is the same as that 
between slavery and freedom. I left a third world  
country to come to the UK thinking that I had jumped 
over the barrier between yes and no, leaving slavery 
behind.
Early in my career as a trainee in histopathology, I 
was reporting a case of a basal cell carcinoma with my 
consultant. His instructions were to report the case 
according to the standards of the minimum dataset 
of the Royal College of Pathologists. This includes 
mentioning whether there is perineural invasion and 
lymphovascular invasion. I am not convinced that this is 
needed in all cases. Perineural invasion is rare and seen 
usually with only one type of basal cell carcinoma. The 
lymphovascular invasion is even rarer, if it occurs at all.
I mentioned this to my consultant, who said I was 
correct but that, as long as these criteria were on the 
dataset, we had to fulfil them.
“Why?” I protested.
“Because this is what the college wants us to do.”
“What if we do not see a point of this?”
“I agree with you, Heyam, but we still cannot say ‘no.’”
What a surprise. Wherever I go, wherever I live, “no” 
is still a difficult word to say.
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